// App-Quantinova.ai

4118 : Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Sandrine J. Faivre

Principal Investigators

  • Robin Katie Kelley

  • Ivelina Gueorguieva

  • Ann Cleverly

  • Durisala Desaiah

  • Michael M. F. Lahn

  • Nicola Murray

  • Karim A. Benhadji

  • Eric Raymond

  • Gianluigi Giannelli

  • Philippe Merle

  • Ed Gane

  • Jean-Yves Douillard

  • Dirk Waldschmidt

  • Mary Frances Mulcahy

  • Charlotte Costentin

  • Beatriz Minguez

  • Pasqua Papappicco

Medical Centers

  • Internal Medicine, Immunology, Infectious Diseases, University of Bari Medical School, Bari, Italy

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Liver Unit, Medical Oncology, Vall dHebron Hospital, Barcelona, Spain

  • Department of Medical Oncology, Besancon University Hospital, Besancon, France

  • Auckland City Hospital, Auckland, New Zealand

  • Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy

  • Hopital Beaujon, Clichy, France

  • Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL

  • Eli Lilly and Company, Indianapolis, IN

  • Hopital de la Croix Rousse, Lyon, France

Locations

  • Italy

  • Germany

  • Spain

  • United States

  • France

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

  • Cadherin 1

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • LY2157299

  • Sorafenib

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT01246986

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved